Articles tagged with Lung Cancer
Researchers developed a novel statistical model to guide targeted therapies based on molecular signatures in tumor biopsies, showing promising results in treating stage IV non-small cell lung cancer. The study found that four drugs targeting specific molecular pathways led to improved disease control and overall survival.
Researchers found that metformin decreases insulin levels and inhibits tumor growth in mice exposed to tobacco carcinogens. Metformin reduced lung tumor burden by 40-72% in treated mice.
A new Lancet editorial promotes the 'eat 5 fruit and veg a day' message despite recent findings suggesting a lower protective effect against cancer. Four key benefits remain: heart disease prevention, strong protection against specific cancers, weight management, and bowel cancer prevention.
Researchers have discovered a novel gene-expression-based approach to define oncogenic pathway signatures in the airway epithelium of smokers with lung cancer. This approach identifies specific genes belonging to the PI3K pathway, which are activated in high-risk smokers and may be reversed with a chemopreventive agent, myo-inositol.
A new study published in the Journal of Thoracic Oncology found that sleeve lobectomy offers superior survival and better postoperative pulmonary function compared to pneumonectomy in selected patients. The study analyzed 210 lung cancer patients and reported lower mortality rates for those who underwent a sleeve lobectomy.
Researchers at the University of Gothenburg have discovered two closely related enzymes, FT and GGT, as promising targets for treating lung cancer. By blocking these enzymes in transgenic mice, they found that cell growth was inhibited, tumour formation decreased, and survival rates improved.
A recent study found that genetic variations in the GPC5 gene are associated with an increased risk of lung cancer in never-smokers. The research, published in The Lancet Oncology, suggests that GPC5 could be a new target for drug development and could help identify high-risk individuals.
A recent study found that approximately 30% of never-smoking lung cancer patients carry a rare variant of the GPC5 gene, leading to reduced expression levels and increased risk of cancer. The research suggests that GPC5 may be a critical tumor suppressor gene in lung cancer development.
Studies reveal significant health disparities among Asian Americans, Native Hawaiians, and Pacific Islanders, with culturally appropriate care shown to reduce cancer rates and heart disease. Immigrant women face high risk of death from breast cancer, while obesity and high blood pressure are major concerns for Native Hawaiians.
A review of gene expression-based prognostic signatures in lung cancer found little evidence to support their clinical application. The studies lacked statistical validation, reproducibility, and clear medical utility, highlighting serious problems with the design and analysis.
Despite progress in cancer research, the disease remains a leading cause of death in the US. Advances in primary prevention, early detection, and treatment have improved outcomes for many cancers, but significant challenges remain, including the need for improved therapies.
Stereotactic body radiation therapy (SBRT) shows high rates of primary tumor control and improved survival for patients with inoperable non-small cell lung cancer. The study's findings suggest that SBRT provides more than double the rate of primary tumor control compared to conventional radiotherapy.
A phase II study found that stereotactic body radiation therapy (SBRT) effectively eliminated targeted tumors in patients with early-stage inoperable non-small cell lung cancer. The treatment resulted in a 97.6% primary tumor control rate at 3 years, outperforming conventional radiotherapy.
A genetic variant identified by researchers at the University of Cincinnati significantly increases lung cancer risk for individuals who smoke lightly, even if they are not heavy smokers. Family members with this genetic variant should be monitored for early detection, regardless of their smoking habits.
Recent studies suggest that triggering TLR7 and TLR8 can actually increase tumor cell survival, while a new soluble factor IFN-beta represses tumor growth by limiting blood vessel formation. Additionally, microRNA-31 has been identified as an oncogenic factor promoting lung cancer through the repression of specific tumor suppressor genes.
A new study suggests that stimulating human lung cancer cells with TLR7 or TLR8 agonists can lead to increased tumor cell survival and resistance to chemotherapy. This approach is being investigated as an adjuvant for anticancer immunotherapies, but caution should be exercised due to these potential risks.
Research found no significant differences in tolerance and efficacy between elderly and non-elderly NSCLC patients receiving salvage targeted therapy or chemotherapy. Elderly patients showed comparable response rates, disease control, and survival times as younger patients.
A new study published in the Journal of Clinical Oncology found that women taking estrogen plus progestin hormone replacement therapy for 10 or more years have a 50% increased risk of developing lung cancer compared to non-users. The study also suggests that duration of use is associated with an advanced stage of cancer at diagnosis.
Researchers found that lung cancer patients with optimistic attitudes had a six-month survival advantage over those with pessimistic attitudes. This study builds on existing research to investigate the effect of patient attitudes on outcomes in oncology populations.
Researchers found that African-Americans are more likely to hold fatalistic beliefs and be reluctant to seek medical attention for lung cancer symptoms. The study suggests that targeted public health messages are needed to address racial disparities in lung cancer treatment outcomes.
A new survey finds that African Americans are more likely to hold misconceptions about lung cancer, which could interfere with prevention and treatment. The study suggests that tailored public health messages are needed to address these disparities.
A large-scale study reveals over 100 genomic sites with missing or duplicated DNA in tumors, uncovering novel cancer genes and genetic abnormalities shared across multiple cancers. The study highlights the importance of common genomic alterations in driving cancer growth.
Research found that split-course palliative radiotherapy reduced patients' symptoms by 52-84% and provided long-lasting relief in 58% of cases. Cancer survival rates were not adversely affected by a two-week break in treatment, demonstrating the regimen's potential as an optimal option for symptom management.
A study of nearly 800 patients with non-small cell lung cancer identified genetic characteristics associated with increased recurrence-free survival, differing between men and women based on age.
The study found that molecular pathways involved in women's lung cancer are less complex than those in men, while elderly patients over 70 have a low-risk profile for long-term survival. The findings may help explain why certain groups of patients do better than others despite having the same disease.
A new approach to smoking cessation uses individualized risk assessments to motivate smokers to quit. Studies show that tests like Respiragene improve quit rates by providing smokers with personalized information about their risk of lung cancer and other smoking-related diseases.
Researchers have discovered that lung cancer tumors alter the odor of bodily fluids, allowing for early detection through trained animal sensors and chemical analysis. The findings hold promise for improving diagnostic and prognostic approaches to lung cancer treatment.
A team of researchers has identified a potential mechanism by which the tobacco-specific carcinogen NNK promotes lung tumor formation. They also found that statins may protect against invasive pneumococcal infections in children with sickle cell disease. Additionally, a new oncogenic protein called Nlp was discovered to be expressed at...
Researchers found that identifying patients with a small number of tumor cells harboring an overabundance of MET even before treatment can produce longer remissions when treated with combination drugs. This suggests that targeting these cells with additional drugs may be beneficial in preventing resistance.
Scientists found that repeated exposure to tobacco smoke made lung cancer worse by causing inflammation in the lungs. The study provided definitive evidence for the role of lung inflammation in promoting lung cancer growth and suggested using anti-inflammatory agents to prevent or slow lung cancer progression.
Researchers identify a potential molecular mechanism by which NNK promotes lung tumor formation and development through DNMT1 accumulation. Accumulation of DNMT1 in lung adenomas from NNK-treated mice and tumors from lung cancer patients correlated with poor prognosis, suggesting an important link between tobacco smoking and lung cancer.
A study published in BMC Public Health found that childhood traumas are associated with an increased risk of developing lung cancer. The researchers analyzed data from over 17,000 individuals and found that those who experienced six or more traumas were approximately three times more likely to develop lung cancer.
The American Association for Cancer Research and International Association for the Study of Lung Cancer honored Dr. Paul A. Bunn Jr., M.D., for his contributions to lung cancer research. The conference emphasized the importance of translational research in improving lung cancer prognosis.
A study found that drinking green tea could reduce the risk of lung cancer in smokers, particularly those with specific genetic profiles. Among smokers, those who drank at least one cup of green tea per day had a significantly lower risk of lung cancer compared to non-green tea drinkers.
A 93-gene signature associated with EGFR mutations in tumors from lung cancer patients was found to be a favorable prognostic marker for early stage lung cancer. The signature is also linked to drug sensitivity to erlotinib and gefitinib in non-small cell lung cancer cell lines.
A study found that erlotinib dosing in lung cancer patients depends on their smoking status, with smokers requiring lower doses than non-smokers. Non-smokers were able to tolerate higher doses without developing grade 2 or 3 toxicity, while smokers reached a maximum tolerated dose of 300mg daily.
A new study has found that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene in their tumors respond significantly to an ALK-inhibitor therapy. The study suggests a paradigm shift in cancer drug development, allowing for more targeted treatments.
A new blood test has been developed to aid in lung cancer diagnosis and potentially reduce unnecessary invasive procedures. The test uses a 40-biomarker panel that correctly identified patients with lung cancer 88% of the time and those without it 79% of the time.
A recent study suggests that retreating patients with non-small cell lung cancer who initially responded to gefitinib treatment could lead to additional partial responses and stable disease. The overall disease control rate was 66.7 percent in the retreatment group, offering hope for patients who have failed initial chemotherapy.
The new T classification is based on tumor size and has been validated as appropriate for pathologic findings. The study found significant differences in survival rates among revised T subsets, highlighting the importance of the revised TMN classification for lung cancer treatment planning.
Researchers at Dana-Farber Cancer Institute have discovered a new compound capable of halting drug-resistant non-small cell lung cancers by targeting a specific protein defect. The pyrimidine WZ4002 has shown promise in restricting cell growth and impeding tumor growth in mice with resistant tumors.
Patients with NSCLC and EGFR mutations showed significantly improved progression-free survival with gefitinib treatment. Gefitinib was also better tolerated than chemotherapy, with fewer severe adverse events.
Researchers found substantial racial and ethnic disparities in cancer survival, particularly in more treatable cancers like breast and prostate cancer. The study suggests that social disadvantage contributes to these disparities, highlighting the need for targeted health policies and interventions.
A study presented at the CTRC-AACR San Antonio Breast Cancer Symposium found that anti-estrogen therapy for breast cancer patients reduced their risk of dying from lung cancer. The research involved 6,715 women diagnosed with breast cancer between 1980 and 2003.
A new mouse model of lung cancer has been developed that replicates the resistance of human lung cancer cells to certain treatments. The study identified secondary mutations in the EGFR gene that contribute to this resistance, which may be targetable with specific drugs.
A diet rich in pistachios may increase dietary intake and serum levels of gamma-tocopherol, potentially reducing lung cancer risk. Pistachio consumption has also been linked to a lower risk of prostate cancer.
Researchers from Yale University and Mirna Therapeutics, Inc., used a naturally occurring tumor suppressor microRNA to reverse the growth of lung tumors in mice. The study found that let-7, a type of micro-RNA, reduced tumors by 66% in mice with non-small cell lung cancer.
A TGen team won a $1,000 prize for their research on identifying microRNAs and imaging features associated with lung cancer metastasis to the brain. The study used microRNAs and imaging characteristics from CT and PET scans as biomarkers to predict brain metastases.
Research analyzed over 100,000 patients with stage IV non-small cell lung cancer and found a modest but statistically significant improvement in one-year and two-year overall survival rates from 13.2% to 19.4% and 4.5% to 7.8%, respectively.
A team of Wistar Institute researchers has identified a 29-gene signature in the blood that can indicate the presence of non-small cell lung cancer at its earliest stages. This discovery could lead to the development of a simple blood test for early-stage lung cancer detection, which would greatly improve treatment outcomes.
New studies show that morphine can boost tumor-cell proliferation and inhibit the immune response, promoting angiogenesis and cancer metastasis. Shielding lung cancer cells from opiates reduces cell proliferation, invasion, and migration in both cell-culture and mouse models.
A new study published in the Journal of the National Cancer Institute found that patient-reported symptoms were more highly associated with day-to-day health status, while clinician reports were more predictive of death and hospitalization. The study suggests that both perspectives are valuable for a comprehensive understanding of trea...
A rapid decline in PET scan activity is correlated with good local tumor control and better lung cancer outcomes. Higher pre-treatment metabolic activity and tumor size are associated with increased risk of death from lung cancer.
A new treatment option has been discovered for patients with early-stage non-small cell lung cancer who are not candidates for surgery. Radical stereotactic radiosurgery performed with CyberKnife leads to a 100% overall survival rate in patients with good lung function, according to a recent study.
A randomized study found that preventative brain radiation for nonsmall cell lung cancer patients decreased the risk of brain metastases by over 50%, but increased short and long-term memory loss. The study also showed no significant difference in overall survival between treated and untreated patients.
Researchers found that nearly 98% of patients with early-stage non-small cell lung cancer who are unable to undergo surgery experienced no growth of the disease after three years. Additionally, over half of these patients lived for three years after diagnosis, while fewer than 20% experienced a serious decline in health status.
The study found that stereotactic body radiation therapy (SBRT) stopped the growth of lung cancer at its original site for nearly 98% of patients with early non-small cell lung cancer. Researchers also discovered that less than 20% of frail patients experienced a serious decline in health status after treatment.
A national clinical trial shows that stereotactic body radiation therapy (SBRT) is effective in treating early-stage lung cancer in patients with unrelated medical comorbidities. The primary lung cancer did not recur 98 percent of the time, and more than half of patients were alive three years after diagnosis.
Research finds that lung cancer patients treated in public hospitals are more likely to have advanced stage cancer than those in private hospitals. The study highlights the need for an organized and timely approach to diagnosis and treatment to reduce health care disparities.
A study confirmed the efficacy of a simple questionnaire in identifying patients at high risk for lung cancer. The questionnaire, completed by over 1,000 patients, found almost half qualified as high risk and led to eight confirmed cases of lung cancer in five years.